Akero Therapeutics, Inc. Common Stock(AKRO)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $41.77 – $57.35
- IV Rank (30D)
- 100
- Straddle Price
- $0.00
- P/C Vol Ratio
- 0.55
- Market Cap
- $4.5B
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $4.5B
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +17.12% | 5 |
| Feb | +1.24% | 5 |
| Mar | -12.92% | 5 |
| Apr | -0.69% | 5 |
| May | +1.03% | 5 |
| Jun | +9.28% | 5 |
| Jul | -0.62% | 5 |
| Aug | +7.25% | 5 |
| Sep | +33.16% | 5 |
| Oct | -8.48% | 5 |
| Nov | +6.50% | 5 |
| Dec | +9.69% | 5 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-09 | After-Close | 8.19% | 2.22% | 0.27x | Within |
| 2024-11-08 | Pre-Market | 9.07% | 0.76% | 0.08x | Within |
| 2025-01-27 | After-Close | 28.17% | 22.51% | 0.80x | Within |
| 2025-05-12 | Pre-Market | 11.15% | 4.09% | 0.37x | Within |
| 2025-08-08 | After-Close | 12.98% | 4.32% | 0.33x | Within |
- IV Rank (30D)
- 100
- IV Rank (7D)
- 100
- Avg IV
- 176.5%
- Straddle (30D)
- $0.00
- Straddle (7D)
- $0.00
- P/C Volume
- 0.55
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 0.33
- Correlation (SPY)
- 9.2%
- R²
- 0.01
- Ann. Volatility
- 39.7%
- SPY Volatility
- 11.0%
Low volatility - stock moves less than market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | WOLVERINE TRADING, LLC Custodian | $433.34K | 100.00% | 2025-09-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | WOLVERINE TRADING, LLC Custodian | $352.39K | 100.00% | 2025-09-30 |
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2025-12-09 | Yuan Xu | Director | Disp (D) | −9,398 | — | EDGAR | |
| 2025-12-09 | Tomas J. Heyman | Director | Disp (D) | −9,398 | — | EDGAR | |
| 2025-12-09 | Jonathan Young | Chief Operating Officer | Disp (D) | −260,189 | — | EDGAR | |
| 2025-12-09 | Jane Henderson | Director | Disp (D) | −9,398 | — | EDGAR | |
| 2025-12-09 | Mark T Iwicki | Director | Disp (D) | −9,398 | — | EDGAR | |
| 2025-12-09 | Scott A. Gangloff | Chief Technology Officer | Disp (D) | −26,351 | — | EDGAR | |
| 2025-12-09 | Patrick Lamy | See Remarks | Disp (D) | −29,891 | — | EDGAR | |
| 2025-12-09 | G. Walmsley Graham | Director | Disp (D) | −1,302,398 | — | EDGAR | |
| 2025-12-09 | William Richard White | Chief Financial Officer | Disp (D) | −57,752 | — | EDGAR | |
| 2025-12-09 | Andrew Cheng | President and CEO | Disp (D) | −436,837 | — | EDGAR | |
| 2025-12-09 | Catriona Yale | Chief Development Officer | Disp (D) | −74,800 | — | EDGAR | |
| 2025-12-09 | Timothy Rolph | Chief Scientific Officer | Disp (D) | −282,149 | — | EDGAR | |
| 2025-12-09 | Seth Loring Harrison | Director | Disp (D) | −293,762 | — | EDGAR | |
| 2025-12-09 | Chou Judy | Director | Disp (D) | −9,398 | — | EDGAR | |
| 2025-11-28 | Timothy Rolph | Chief Scientific Officer | Exer (M) | +152,678 | $4.09 | $624.1K | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Versant Venture Capital VI, L.P. | 10%+ Owner | 7,297,318 | $398.80M | -$24.20M | 8 | 2020-07-10 |
| 2 | ATP III GP, Ltd. | 10%+ Owner | 5,830,203 | $318.62M | $29.88M | 1 | 2020-07-14 |
| 3 | Aaron Royston | Director | 3,954,858 | $216.13M | $4.00M | 1 | 2019-06-25 |
| 4 | COREY S GOODMAN | 10%+ Owner | 3,940,534 | $215.35M | -$1.72M | 1 | 2020-01-03 |
| 5 | Versant Ventures VI GP-GP, LLC | 10%+ Owner | 3,309,616 | $180.87M | -$4.28M | 1 | 2020-01-06 |
| 6 | Montrago Trustees Ltd | 3,271,829 | $178.81M | -$284.66M | 1 | 2022-12-05 | |
| 7 | venBio Global Strategic GP II, L.P. | 10%+ Owner | 3,229,548 | $176.49M | $11.23M | 4 | 2020-02-27 |
| 8 | venBio Global Strategic GP II, Ltd. | 10%+ Owner | 3,160,319 | $172.71M | -$59.45M | 4 | 2020-03-06 |
| 9 | Versant Ventures VI GP, L.P. | 10%+ Owner | 3,118,638 | $170.43M | -$6.91M | 2 | 2020-01-21 |
| 10 | Robert J Adelman | 10%+ Owner | 3,033,552 | $165.78M | -$35.50M | 4 | 2020-07-06 |
| 11 | Atlas Venture Fund XI, L.P. | 10%+ Owner | 2,706,412 | $147.91M | $0 | 1 | 2020-01-02 |
| 12 | Jeremy Green | 10%+ Owner | 743,802 | $40.65M | $0 | 1 | 2019-06-24 |
| 13 | Atlas Venture Associates Opportunity I, L.P. | 10%+ Owner | 505,099 | $27.60M | $25.92M | 1 | 2019-06-25 |
| 14 | Atlas Venture Opportunity Fund I, L.P. | 10%+ Owner | 404,079 | $22.08M | $0 | 2 | 2020-02-10 |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.